Analystreport

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at Roth Capital. They set a "buy" rating and a $7.00 price target on the stock.

Sorrento Therapeutics, Inc.  (SRNE) 
Last sorrento therapeutics, inc. earnings: 8/9 04:49 pm Check Earnings Report
US:NASDAQ Investor Relations: sorrentotherapeutics.com/investors